[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629735":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":10,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Stockolm3 Blood test in prostate cancer patient under active surviellance",null,"Diagnostic procedure",[13],"Diagnostic Test: Stockholm3",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Stockholm3","Predictive value of Stockholm3 test in a prostate cancer cohort on Active Surveillance (AS) for upgrading on re-biopsy",[9],[21],{"name":22,"affiliation":23,"role":24},"Beat Roth, Prof. Dr. med.","Inselspital, University Hospital of Bern","STUDY_CHAIR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Nicola Giudici, Dr.","CONTACT","+41316322332","urologie.studienmanagement@insel.ch",{"name":32,"role":28,"phone":29,"phoneExt":10,"email":33},"Anselm Lafita, CRC","anselm.lafita@insel.ch",[35],{"facility":23,"status":10,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Bern","Canton of Bern","3010","Switzerland","CH",{"type":42,"coordinates":43},"Point",[44,45],7.44744,46.94809,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":29,"phoneExt":10,"email":30},"Lafita Anselm, CRC",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100629735","stockholm3-test-validation-in-men-on-active-surveillance-in-switzerland-chas3-trial-100629735",false,"NCT07478536","Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)","Multicenter Validation of the Stockholm3 Test on Men on Active Surveillance: the CHAS3-Trial","CHAS3","Inclusion Criteria:\n\n* Adult Men ≥ 18 y. o.\n* Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS)\n* First inclusion in Active Surveillance (AS) after 1st January 2022.\n* Scheduled for follow-up with systematic and\u002For Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available\n\nExclusion Criteria:\n\n* \\- Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy).\n\n  * Patient with intermediate- or high-risk prostate cancer\n  * Urinary catheterization within the past 6-8 weeks\n  * Contraindications to Magnetic Resonance Imaging (MRI) or biopsy","MALE",{"count":62,"type":63},350,"ESTIMATED","OBSERVATIONAL","The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.",[67,68],"Prostate Cancer","Active Surveillance for Prostate Cancer",[70,71,72,17,73,74],"Prostate","Cancer","Active Surveillance","MRI","Biopsie","NOT_YET_RECRUITING","2026-06-18",{"date":78,"type":79},"2026-06-22","ACTUAL",{"date":81,"type":63},"2026-07-01",{"date":83,"type":63},"2028-08-31",{"name":5,"class":6},1]